Linked Life Data

21463652

Source:http://linkedlifedata.com/resource/pubmed/id/21463652

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21463652rdf:typepubmed:Citationlld:pubmed
pubmed-article:21463652lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:21463652lifeskim:mentionsumls-concept:C0012634lld:lifeskim
pubmed-article:21463652lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:21463652lifeskim:mentionsumls-concept:C1516691lld:lifeskim
pubmed-article:21463652lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:21463652lifeskim:mentionsumls-concept:C1627358lld:lifeskim
pubmed-article:21463652pubmed:issue2lld:pubmed
pubmed-article:21463652pubmed:dateCreated2011-6-13lld:pubmed
pubmed-article:21463652pubmed:abstractTextThe investigation of novel drug targets for treating cognitive impairments associated with neurological and psychiatric disorders remains a primary focus of study in central nervous system (CNS) research. Many promising new therapies are progressing through preclinical and clinical development, and offer the potential of improved treatment options for neurodegenerative diseases such as Alzheimer's disease (AD) as well as other disorders that have not been particularly well treated to date like the cognitive impairments associated with schizophrenia (CIAS). Among targets under investigation, cholinergic receptors have received much attention with several nicotinic agonists (?7 and ?4?2) actively in clinical trials for the treatment of AD, CIAS and attention deficit hyperactivity disorder (ADHD). Both glutamatergic and serotonergic (5-HT) agonists and antagonists have profound effects on neurotransmission and improve cognitive function in preclinical experiments with animals; some of these compounds are now in proof-of-concept studies in humans. Several histamine H3 receptor antagonists are in clinical development not only for cognitive enhancement, but also for the treatment of narcolepsy and cognitive deficits due to sleep deprivation because of their expression in brain sleep centers. Compounds that dampen inhibitory tone (e.g., GABA(A) ?5 inverse agonists) or elevate excitatory tone (e.g., glycine transporter inhibitors) offer novel approaches for treating diseases such as schizophrenia, AD and Down syndrome. In addition to cell surface receptors, intracellular drug targets such as the phosphodiesterases (PDEs) are known to impact signaling pathways that affect long-term memory formation and working memory. Overall, there is a genuine need to treat cognitive deficits associated with many neuropsychiatric conditions as well as an increasingly aging population.lld:pubmed
pubmed-article:21463652pubmed:languageenglld:pubmed
pubmed-article:21463652pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21463652pubmed:citationSubsetIMlld:pubmed
pubmed-article:21463652pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21463652pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21463652pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21463652pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21463652pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21463652pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21463652pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21463652pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21463652pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21463652pubmed:statusMEDLINElld:pubmed
pubmed-article:21463652pubmed:monthAuglld:pubmed
pubmed-article:21463652pubmed:issn1873-5177lld:pubmed
pubmed-article:21463652pubmed:authorpubmed-author:BallardTheres...lld:pubmed
pubmed-article:21463652pubmed:authorpubmed-author:PouzetBrunoBlld:pubmed
pubmed-article:21463652pubmed:authorpubmed-author:RiedelWim JWJlld:pubmed
pubmed-article:21463652pubmed:authorpubmed-author:WallaceTanya...lld:pubmed
pubmed-article:21463652pubmed:authorpubmed-author:WettsteinJose...lld:pubmed
pubmed-article:21463652pubmed:copyrightInfoCopyright © 2011 Elsevier Inc. All rights reserved.lld:pubmed
pubmed-article:21463652pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21463652pubmed:volume99lld:pubmed
pubmed-article:21463652pubmed:ownerNLMlld:pubmed
pubmed-article:21463652pubmed:authorsCompleteYlld:pubmed
pubmed-article:21463652pubmed:pagination130-45lld:pubmed
pubmed-article:21463652pubmed:meshHeadingpubmed-meshheading:21463652...lld:pubmed
pubmed-article:21463652pubmed:meshHeadingpubmed-meshheading:21463652...lld:pubmed
pubmed-article:21463652pubmed:meshHeadingpubmed-meshheading:21463652...lld:pubmed
pubmed-article:21463652pubmed:meshHeadingpubmed-meshheading:21463652...lld:pubmed
pubmed-article:21463652pubmed:meshHeadingpubmed-meshheading:21463652...lld:pubmed
pubmed-article:21463652pubmed:meshHeadingpubmed-meshheading:21463652...lld:pubmed
pubmed-article:21463652pubmed:meshHeadingpubmed-meshheading:21463652...lld:pubmed
pubmed-article:21463652pubmed:meshHeadingpubmed-meshheading:21463652...lld:pubmed
pubmed-article:21463652pubmed:meshHeadingpubmed-meshheading:21463652...lld:pubmed
pubmed-article:21463652pubmed:meshHeadingpubmed-meshheading:21463652...lld:pubmed
pubmed-article:21463652pubmed:meshHeadingpubmed-meshheading:21463652...lld:pubmed
pubmed-article:21463652pubmed:meshHeadingpubmed-meshheading:21463652...lld:pubmed
pubmed-article:21463652pubmed:meshHeadingpubmed-meshheading:21463652...lld:pubmed
pubmed-article:21463652pubmed:meshHeadingpubmed-meshheading:21463652...lld:pubmed
pubmed-article:21463652pubmed:year2011lld:pubmed
pubmed-article:21463652pubmed:articleTitleDrug targets for cognitive enhancement in neuropsychiatric disorders.lld:pubmed
pubmed-article:21463652pubmed:affiliationCenter for Neuroscience, SRI International, Menlo Park, CA, USA.lld:pubmed
pubmed-article:21463652pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21463652pubmed:publicationTypeReviewlld:pubmed